Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Pfizer
Eli Lilly and Company
Pfizer
Pfizer
SWOG Cancer Research Network
Institut du Cancer de Montpellier - Val d'Aurelle
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Institut Bergonié
Pfizer
TheraOp
Sixth Affiliated Hospital, Sun Yat-sen University
Mirati Therapeutics Inc.
Fudan University
Tang-Du Hospital
Canadian Cancer Trials Group
Canadian Cancer Trials Group
Eastern Cooperative Oncology Group
Amgen
Medical Research Council
Fox Chase Cancer Center
Alliance for Clinical Trials in Oncology
Merck Sharp & Dohme LLC
Abramson Cancer Center at Penn Medicine
National Cancer Institute (NCI)
UNICANCER
University of Wisconsin, Madison
Korea Cancer Center Hospital
Novartis
Dana-Farber Cancer Institute
Eli Lilly and Company
SWOG Cancer Research Network
Alliance for Clinical Trials in Oncology
RenJi Hospital
Stanford University
University College, London
National Institutes of Health Clinical Center (CC)
Alliance for Clinical Trials in Oncology
US Oncology Research
University of Pittsburgh
Alliance for Clinical Trials in Oncology
Memorial Sloan Kettering Cancer Center
Centro Nacional de Investigaciones Oncologicas CARLOS III
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Swedish Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)